29 April 2026: Articles
A Rare Case of Stevens-Johnson Syndrome in a Young Patient Presenting With Odynophagia Following Antibiotic Use
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Rare disease, Adverse events of drug therapy, Clinical situation which can not be reproduced for ethical reasons
John Tomasini AEF 1*, Joanna SajdlowskaDOI: 10.12659/AJCR.951823
Am J Case Rep 2026; 27:e951823
Abstract
BACKGROUND: Stevens-Johnson syndrome (SJS) is a rare, immune-mediated mucocutaneous disorder usually triggered by medications or infections. It typically manifests with widespread epidermal detachment and mucosal ulcerations, but atypical cases can present with isolated mucosal involvement, leading to diagnostic uncertainty and delayed treatment. Recognizing such varying presentations is crucial to precent progression to more severe disease and improve outcomes.
CASE REPORT: We present the case of an 18-year-old male with no significant medical history who presented with severe odynophagia, oral ulcerations, conjunctivitis, and dysuria shortly after completing a course of cefdinir for an upper respiratory infection. Notably, he lacked the characteristic diffuse rash seen in classic SJS. Laboratory evaluation revealed elevated inflammatory markers, and imaging demonstrated non-specific soft tissue edema. Initial management included cessation of cefdinir, intravenous fluids, corticosteroids, and broad supportive care. During hospitalization, he developed macular lesions on the palms and soles and progressive mucosal sloughing. Serologic testing later confirmed elevated Mycoplasma pneumoniae IgM and IgG titers, leading to reclassification of this condition to Mycoplasma pneumoniae-associated SJS (MP-SJS). He was treated with intravenous immunoglobin and azithromycin, with gradual improvement and full recovery after a 2-week hospital course.
CONCLUSIONS: This case highlights an atypical, mucosal-predominant presentation of Mycoplasma pneumoniae-associated SJS in an adolescent male, initially mimicking severe oropharyngeal infection. Clinicians should maintain a high index of suspicion for SJS in patients presenting with acute mucositis and odynophagia following recent medication use or respiratory illness, even when the cutaneous findings are absent. Early identification, withdrawal of the offending agent, and prompt multidisciplinary care are critical to favorable outcomes.
Keywords: Autoimmune Diseases, mucositis, Stevens-Johnson Syndrome
Introduction
Stevens-Johnson syndrome (SJS) is a rare but life-threatening mucocutaneous hypersensitivity reaction characterized by extensive keratinocyte apoptosis, epidermal detachment, and mucosal involvement affecting the oral, ocular, and genital regions. It involves less than 10% of the body surface area and carries a high risk of morbidity and mortality if not promptly diagnosed and managed. The annual incidence of SJS in the United States is approximately 1 to 5 cases per million, underscoring its rarity in the general population [1].
The pathogenesis of SJS is primarily immune-mediated, with growing evidence pointing to a delayed-type hypersensitivity reaction that is both HLA class I-restricted and CD8+ T-cell driven [2]. This understanding has led to preventive strategies, such as screening for the HLA-B*15: 02 allele in certain populations prior to prescribing high-risk medications like carbamazepine [3].
Drug exposure is the most common trigger, with anticonvulsants, sulfonamides, and antibiotics such as cephalosporins being among the most frequently implicated [4]. Other etiologies include infections, notably
Clinically, SJS presents with a prodrome of fever, malaise, pharyngitis, and conjunctivitis, followed by the appearance of painful, erythematous macules that evolve into vesicles and erosions [6]. The mucosa is affected in over 85% of cases involving oral and genital mucosa, as well as the conjunctiva [2].
Despite the robust documentation of SJS in adults, its presentation in pediatric and adolescent populations is significantly less common [7]. Even more rare are cases that present with isolated oropharyngeal symptoms, particularly odynophagia (painful swallowing) as the initial or predominant concern. Compared with more typical manifestations involving skin and mucosal involvement [8], such atypical presentations can complicate the diagnostic process and delay definitive management, especially when cutaneous lesions are absent or emerge later in the disease course. Differential diagnoses for early or atypical SJS presenting with isolated oropharyngeal involvement may include herpes simplex virus (HSV), Bechet disease, recurrent aphthous stomatitis, herpangina (Coxsackievirus A), hand, foot, and mouth disease (HFMD),
In this report, we describe a diagnostically challenging and clinically significant case of SJS in an otherwise healthy adolescent male. This case highlights the novelty of a mucosal-predominant presentation and underscores the importance of maintaining a high index of suspicion for SJS in the differential diagnosis of oropharyngeal pain – particularly in the setting of recent drug exposure – and contributes to the limited literature on atypical pediatric presentations.
Case Report
An 18-year-old male with no significant past medical history presented to the emergency department with a 2-day history of sore throat with odynophagia, a burning sensation intraorally, and poor oral intake. He reported 2 episodes of emesis and subjective fever. Additionally, he had dry, pruritic eyes and pain on urination. Four days prior to the hospital visit, he developed symptoms of nasal congestion, sinus pain, and mild sore throat. He was examined by a general practitioner and was diagnosed with post-nasal drip for which he was prescribed cefdinir and fexofenadine. After a week, symptoms had not resolved and progressively worsened, which prompted the visit to the emergency department. Initially, he was treated for an allergic reaction, nausea, and vomiting with epinephrine, famotidine, ondansetron, and pain medication. He was afebrile and denied any respiratory, chest, or abdominal symptoms. A CT neck soft tissue with contrast showed non-specific patchy subcutaneous/soft tissue edema. Laboratory studies were suspicious for an infectious process as white blood cell count and C-reactive protein were elevated at 12.1×103/mm3 and 11.4 mg/dL, respectively; complete metabolic panel revealed hyponatremia; respiratory viral panel and strep test were both negative. An STI panel came back negative. Throat and urine cultures were collected.
Upon physical examination, the patient appeared distressed. Vital signs were as follows: temperature 36.8°C, heart rate 62 beats per minute, blood pressure 135/64 mmHg, respiratory rate 18 beats per minute, and oxygen saturation 99% on room air. Pertinent findings on the head and neck examination included bilateral conjunctival injection with dry-appearing eyes and mild chemosis. Sialorrhea was present. The upper and lower lips were edematous and erythematous with hemorrhagic crusting and exudate. Intraorally, there were generalized, ulcerative, and erosive lesions noted on the buccal and labial mucosa, floor of mouth, ventral and dorsal tongue, and hard palate. Gingival desquamation was present with positive Nikolsky’s sign. The oropharynx was difficult to examine due to pain and severe gag reflex; however, erythema and edema were appreciable, with enlarged bilateral tonsils. Cranial nerves V and VII were found to be grossly intact.
The patient was admitted to the pediatric floor with a working diagnosis of Stevens-Johnson syndrome secondary to cefdinir use. Given the recent exposure to a cephalosporin temporally associated with symptom onset, cefdinir was initially suspected as the inciting agent and was discontinued. The patient was started on aggressive intravenous (IV) fluids, methylprednisolone 4 mg/kg/day, and clindamycin for antimicrobial coverage during wound healing. Acetaminophen, ketorolac, magic mouthwash (numbing agent, antacid, diphenhydramine, corticosteroid, antifungal), and triamcinolone acetonide 0.1% were ordered for pain control. Per ophthalmology recommendations, prednisolone acetate eye drops, erythromycin ophthalmic ointment, and artificial tears were ordered.
Early in his hospital course, he became progressively worse with increased intensity of symptoms, including multiple episodes of fever and development of an erythematous, macular rash on the palms and soles of the hands and feet, without pruritus (Figures 1, 2). The eyes and mouth showed increased erythema, edema, and crusting (Figure 3). New-onset pain during inspiration through the nose developed, which was attributed to sloughing of nasal mucosa. The skin overlying the scrotum became extremely sensitive and irritated along with mucosal sloughing around the urethra. On hospital day 3, throat swabs were again collected and sent for PCR, which were positive for
Towards the end of his 2-week hospital course, he showed significant improvement, with almost complete resolution of symptoms. He was able to tolerate oral intake, with a normal diet. The genital and ocular symptoms had resolved, as did the cutaneous rash. Methylprednisolone dosing was gradually reduced and the patient was discharged with a 3-day steroid taper, pain medication, and prednisolone ophthalmic ointment.
After discharge, he remained clinically stable and had full resolution of the mucosal and skin lesions. He was seen for a 2-month follow up at the infectious disease clinic, where he was symptom-free and no longer using any mediations. There were no notable findings other than geographic tongue. He was able to return to his daily life, including attendance at his high school senior prom and graduation.
Discussion
SJS is a rare mucocutaneous disorder characterized by erosions and epidermal detachment. It is widely regarded as a dermatologic and medical emergency, typically triggered by medications or infections. SJS involves <10% of total body surface area, and frequently affects multiple mucosal sites, including the oral, ocular, and genital mucosa [9]. One to 5% of patients with SJS will succumb to this condition. It is similar to but less severe than toxic epidermal necrolysis (TEN), which involves over 30% of total body surface area and has a mortality rate of 25% to 30% [10]. Our patient initially presented with odynophagia and mucosal ulceration in the absence of skin involvement – a presentation that differs from classic descriptions and emphasizes the novelty of this mucosal-predominant variant, particularly in children and adolescents.
While the classic presentation of SJS involves a prodrome of fever and malaise, followed by widespread erythematous macules or targetoid lesions and mucosal ulceration, several reports have documented mucosal-predominant or mucosal-only variants [11]. A retrospective analysis by Frantz et al found that mucosal involvement can precede skin findings by several days, particularly in younger patients or those with
Our patient’s primary concern of odynophagia, with subsequent development of oral and genital ulceration, is an example of a mucosal-predominant variant. Such cases have been historically misdiagnosed as viral pharyngitis, aphthous ulcers, or herpetic stomatitis, often delaying appropriate treatment [13]. A positive Nikolsky’s sign and rapid spread of mucosal desquamation should prompt clinicians to consider SJS, even in the absence of classic cutaneous signs.
Antibiotics are the medications most frequently associated with the onset of SJS, particularly sulfonamides, beta-lactam agents, and cephalosporins; however, infection-associated SJS, particularly with
The use of systemic corticosteroids in SJS remains controversial. While some studies suggest increased risk of infection and delayed healing, others have demonstrated potential benefit when administered early in the disease course [18]. In our case, methylprednisolone was initiated empirically and tapered with clinical improvement, consistent with data supporting short-term corticosteroids in selected cases, particularly MP-SJS [19]. Additionally, the use of IVIG was guided by the presumed immunologic etiology. Although randomized controlled data are limited, IVIG has shown variable benefit in SJS, potentially by blocking Fas-FasL-mediated keratinocyte apoptosis [20]. A 2019 meta-analysis by Zimmermann et al found that high-dose IVIG combined with corticosteroids can reduce mortality, particularly in pediatric populations [21].
Optimal management of SJS requires a multidisciplinary approach – including dermatology, ophthalmology, infectious disease, ENT, or oral and maxillofacial surgery – and critical care, as well as rigorous supportive therapy. Our patient received comprehensive management involving pain control, maintenance of hydration, ocular lubrication, and meticulous mucosal wound care. Ophthalmologic involvement is critical, as up to 50% of SJS/TEN survivors develop long-term ocular complications, including symblepharon and corneal scarring, and, in severe cases, blindness.
This case illustrates the need for clinical vigilance in recognizing early SJS, particularly in adolescents presenting with mucosal concerns and recent antibiotic exposure or respiratory illness. Mucosal-predominant SJS is likely under-recognized, and delays in diagnosis can lead to unnecessary morbidity. Prompt withdrawal of the offending agent, targeted antimicrobial therapy (in cases of MP-SJS), and aggressive supportive care remain the cornerstones of treatment. This case also reinforces the utility of repeating diagnostic tests, including PCR and serologies for atypical pathogens, when the clinical course does not improve as expected.
Conclusions
SJS should be considered in patients with acute-onset painful mucositis, odynophagia, and ocular or genital symptoms, even in the absence of skin involvement. This case adds to the limited reports of mucosal-predominant MP-SJS in adolescents and demonstrates how the initial presentation can mimic benign oropharyngeal disease.
Figures
Figure 1. Macular lesions on the patient’s left footClinical photograph showing erythematous, non-pruritic macular lesions on the plantar surface of the left foot. The lesions demonstrate early cutaneous involvement characteristic of Stevens-Johnson syndrome (SJS), appearing after the onset of mucosal symptoms. No vesiculation or epidermal detachment is noted at this stage. Image taken under ambient clinical lighting using a mobile digital camera (no magnification).
Figure 2. Erythematous macular rash on the left palmClinical image depicting multiple erythematous macular lesions across the left palm without evidence of blistering or desquamation. These lesions appeared several days after the oral findings and support the diagnosis of systemic Stevens-Johnson syndrome. Photograph obtained under ambient room light, no magnification, normal color balance preserved.
Figure 3. Severe Oral mucosal sloughing and erythemaIntraoral photograph demonstrating diffuse ulcerative and erosive lesions involving the buccal and labial mucosa. There is marked erythema, edema, and hemorrhagic crusting of the lips, with positive Nikolsky’s sign. These findings are consistent with severe mucosal involvement in SJS. Image captured under natural overhead lighting in the sagittal plane using a mobile digital camera, no staining or magnification applied. References
1. Marks GB, Thompson V, Nguyen S, Epidemiology, diagnosis, and management of Stevens-Johnson syndrome: An updated review: J Invest Dermatol, 2023; 143(1); 15-27
2. Zimmerman S, Hoang Dang N, Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical presentation, and management: JAMA Dermatol, 2019; 155(4); 442-46
3. Phillips EJ, Sukasem C, Whirl-Carrillo M, Clinical pharmacogenetics implementation: Screening for HLA-B*15: 02 prior to carbamazepine therapy: N Engl J Med, 2017; 377(12); 1111-20
4. Gerull R, Nelle M, Schaible T, Toxic epidermal necrolysis and Stevens-Johnson syndrome: A review: Crit Care Med, 2011; 39(6); 1521-32
5. Bastuji-Garin S, Rzany B, Stern RS, Clinical classification of cases of Stevens-Johnson syndrome, toxic epidermal necrolysis, and erythema multiforme: Arch Dermatol, 2000; 136(6); 726-32
6. Chantapakhul T, Suchonwanit P, Khunkhet S, Mucosal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: Dermatol Clin, 2015; 33(1); 63-70
7. Shah AS, Keller M, Enomoto LM, Pediatric Stevens-Johnson syndrome: A multicenter review and management update: Pediatr Dermatol, 2024; 41(2); 215-22
8. Lucia SP, Vega-Castro J, Requena L, Isolated oral mucosal involvement in Stevens-Johnson syndrome: A diagnostic challenge: Oral Surg Oral Med Oral Pathol Oral Radiol, 2019; 127(1); e13-e17
9. Harr T, French LE, Toxic epidermal necrolysis and Stevens-Johnson syndrome: Orphanet J Rare Dis, 2010; 5; 39
10. Trayes KP, Love G, Studdiford JS, Stevens-Johnson syndrome and toxic epidermal necrolysis: Diagnosis, prevention, and management: Am Fam Physician, 2019; 100(10); 610-18
11. Labib A, Milroy C, Toxic epidermal necrolysis: StatPearls [Internet], 2025, Treasure Island (FL), StatPearls Publishing Updated May 8, 2023
12. Frantz R, Huang L, Are D, Mucosal-predominant Stevens-Johnson syndrome in children: A diagnostic challenge: Pediatr Dermatol, 2021; 38(2); 364-68
13. Hoetzenecker W, Nägeli M, Mehra ET, Adverse cutaneous drug eruptions: Current understanding: Semin Immunopathol, 2016; 38(1); 75-86
14. Roujeau JC, Stern RS, Severe adverse cutaneous reactions to drugs: N Engl J Med, 1994; 331(19); 1272-85
15. Ravin KA, Rappaport LD, Zuckerbraun NS: Pediatrics, 2007; 119(4); e1002-e5
16. Canavan TN, Mathes EF, Frieden I, Shinkai K: J Am Acad Dermatol, 2015; 72(2); 239-45
17. Mockenhaupt M, Viboud C, Dunant A, Stevens-Johnson syndrome and toxic epidermal necrolysis: Assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study: J Invest Dermatol, 2008; 128(1); 35-44
18. Schneider JA, Cohen PR, Stevens-Johnson syndrome and toxic epidermal necrolysis: A concise review with a comprehensive summary of therapeutic interventions emphasizing supportive measures: Adv Ther, 2017; 34(6); 1235-44
19. Kim HI, Kim SW, Yoon HS, Clinical features and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis: A comparison of steroid and non-steroid treatment protocols: J Korean Med Sci, 2012; 27(5); 527-33
20. Viard I, Wehrli P, Bullani R, Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin: Science, 1998; 282(5388); 490-93
21. Zimmermann S, Sekula P, Venhoff M, Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis: JAMA Dermatol, 2017; 153(6); 514-22
Figures
Figure 1. Macular lesions on the patient’s left footClinical photograph showing erythematous, non-pruritic macular lesions on the plantar surface of the left foot. The lesions demonstrate early cutaneous involvement characteristic of Stevens-Johnson syndrome (SJS), appearing after the onset of mucosal symptoms. No vesiculation or epidermal detachment is noted at this stage. Image taken under ambient clinical lighting using a mobile digital camera (no magnification).
Figure 2. Erythematous macular rash on the left palmClinical image depicting multiple erythematous macular lesions across the left palm without evidence of blistering or desquamation. These lesions appeared several days after the oral findings and support the diagnosis of systemic Stevens-Johnson syndrome. Photograph obtained under ambient room light, no magnification, normal color balance preserved.
Figure 3. Severe Oral mucosal sloughing and erythemaIntraoral photograph demonstrating diffuse ulcerative and erosive lesions involving the buccal and labial mucosa. There is marked erythema, edema, and hemorrhagic crusting of the lips, with positive Nikolsky’s sign. These findings are consistent with severe mucosal involvement in SJS. Image captured under natural overhead lighting in the sagittal plane using a mobile digital camera, no staining or magnification applied. In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






